Breztri is NOT appropriate for cough-variant asthma
Breztri (budesonide/glycopyrrolate/formoterol) is FDA-approved exclusively for COPD maintenance treatment and is explicitly NOT indicated for asthma treatment 1. The FDA label clearly states it is "not indicated for the treatment of asthma" and warns that "it is not known if BREZTRI AEROSPHERE is safe and effective in people with asthma" 1.
What Should Be Prescribed Instead
For cough-variant asthma, inhaled corticosteroids (ICS) should be first-line treatment, with the option of adding a leukotriene receptor antagonist if response is incomplete 2. The CHEST guideline specifically recommends:
- Start with ICS alone as first-line therapy for cough-variant asthma
- If incomplete response: step up the ICS dose and consider adding a leukotriene inhibitor
- Beta-agonists (like albuterol) can be considered in combination with ICS, not as monotherapy 2
The Evidence for Appropriate Treatment
The 2020 NAEPP guidelines support two evidence-based approaches for mild persistent asthma (which includes cough-variant asthma) in patients ≥12 years 3:
- Daily low-dose ICS + as-needed SABA (traditional approach)
- As-needed ICS + SABA used concomitantly (newer approach)
Recent high-quality evidence demonstrates that budesonide-formoterol used as-needed is highly effective for mild asthma. The MANDALA trial (2022) showed that as-needed albuterol-budesonide combination reduced severe exacerbations by 26% compared to albuterol alone 4. The Novel START trial (2019) found as-needed budesonide-formoterol reduced exacerbations by 51% versus albuterol alone 5.
Specific Treatment Algorithm for Cough-Variant Asthma
Step 1: Initiate low-dose ICS (e.g., budesonide 200 mcg twice daily) + as-needed albuterol
Step 2: If cough persists after 2-4 weeks:
- Increase ICS dose, OR
- Add montelukast 10 mg daily
- Research shows montelukast alone, budesonide/formoterol alone, or their combination all effectively reduce cough symptoms with similar efficacy 6
Step 3: Consider as-needed budesonide-formoterol combination (when available as a single inhaler) as an alternative strategy, which provides lower total steroid exposure while maintaining efficacy 5, 7
Critical Pitfalls to Avoid
Do not use LABA without ICS in asthma. LABAs alone increase mortality risk in asthma patients. Breztri contains formoterol (LABA) plus glycopyrrolate (LAMA), which is a COPD-specific combination not validated for asthma 1.
Do not use anticholinergics (like glycopyrrolate in Breztri) as primary therapy for asthma. While LAMAs have emerging roles in severe uncontrolled asthma as add-on therapy, they are not first-line for cough-variant asthma 2.
Albuterol as-needed alone is appropriate for rescue therapy but should always be paired with controller therapy (ICS) in persistent asthma, including cough-variant asthma 3, 2.
Why This Matters
Using Breztri for asthma represents off-label use of a medication not studied or approved for this indication. The triple therapy combination (ICS/LAMA/LABA) is designed for COPD pathophysiology, which differs fundamentally from asthma. Cough-variant asthma responds well to ICS-based therapy, with 86.3% of patients showing improvement with budesonide-formoterol 8, making the addition of an anticholinergic unnecessary and potentially exposing patients to additional side effects (urinary retention, glaucoma risk) without proven benefit 1.